Melinta Therapeutics (MLNT) Provides Updates on Strategic Repositioning Initiatives, Cost Savings Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Melinta Therapeutics Provides Corporate Updates
February 4, 2019 8:00 AM EST~ Highlights Continued Positive Sales Momentum and Estimated Year-End Cash Position ~
~ Confirms Previously Announced Cost Savings Guidance ~Â ~ Continues Senior Leadership Team Evolution with New Management Appointments ~
NEW HAVEN, Conn., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today provided an update on its strategic repositioning initiatives, cost savings outlook, as well as new management appointments. The Company continues to execute on its strategic initiatives... More
